ArticleFrontiers in oncology2026
The clinical landscape of bladder cancer treatment: a brief report on new developments and future perspectives in pharmaceutical interventions.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study systematically delineates the clinical research status and trends in bladder cancer (Bca) therapeutics through an analysis of 1024 Bca drug treatment clinical trials identified from a harmonised search of the Trialtrove database, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) database as of December 31, 2025. The results demonstrate that the overall number of clinical trials has tended to increase, with a subsequent decline observed in the post-COVID-19 period; the United States has led research efforts, followed by China, the United Kingdom, Canada, and Australia, which together account for 68.6% of all registered trials; the therapeutic focus has shifted from traditional chemotherapy toward immunotherapy (38.4% of trials, primarily targeting PD-1, PD-L1 and ICIs) and targeted therapies [24.7% of trials, e.g., FGFR inhibitors and Nectin-4-targeting antibody-drug conjugates (ADCs)]. Among validated clinical advances, the EV-302 trial established enfortumab vedotin plus pembrolizumab as the first-line standard of care for locally advanced or metastatic urothelial carcinoma. However, the high trial registration frequency does not uniformly translate into clinical benefit, as exemplified by the subsequent withdrawal of atezolizumab's bladder cancer indications following negative confirmatory phase III results. In the future, molecular subtype-based personalized treatment strategies, including circulating tumor DNA (ctDNA)-guided adjuvant therapy, novel ADC combination strategies, and artificial intelligence (AI)-driven multiomics integration, will be pivotal for enhancing therapeutic outcomes in Bca.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.